The HNCG aims to contribute to a better management of patients with HN cancer at various stages of their disease by promoting and validating new treatment paradigms, and to improve the understanding of the disease by deciphering the individual determinants of response to therapy.
Debiopharm and EORTC announce a collaboration to investigate Triptorelin for treatment of Salivary Gland Cancers 13/01/2016
DATECAN initiative publishes Guidelines for time-to-event end point definitions in breast cancer trials 19/05/2015
EORTC trial evaluates androgen deprivation therapy for patients with recurrent / metastatic androgen receptor expressing 10/02/2015
EORTC and DAHANCA launch trial for patients with locally advanced squamous cell carcinoma of the head and neck 04/06/2014
EORTC trial opens for patients with differentiated or medullary thyroid cancer progressing after first line therapy 20/05/2014
EORTC head & neck cancer trial shows assessing HRQOL is valuable to both patients and their doctors 20/11/2013
Addressing treatment resistance in patients with squamous cell carcinoma of head and neck with Pr. Machiels and Blanpain 13/09/2013